Published in N Engl J Med on March 22, 1990
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
Events per person year--a dubious concept. BMJ (1995) 2.65
Current and potential future drug treatments for osteoporosis. Ann Rheum Dis (1996) 2.21
Biomarkers and surrogate markers: an FDA perspective. NeuroRx (2004) 2.20
Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ (1991) 2.12
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest (1998) 1.75
A biomechanical perspective on bone quality. Bone (2006) 1.53
Bone mass measurements: reasons to be cautious. BMJ (1994) 1.38
Feasibility of in vivo structural analysis of high-resolution magnetic resonance images of the proximal femur. Osteoporos Int (2005) 1.38
Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int (2003) 1.33
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ (1992) 1.27
Fluoride's effects on the formation of teeth and bones, and the influence of genetics. J Dent Res (2010) 1.23
The need for randomization in animal trials: an overview of systematic reviews. PLoS One (2014) 1.22
Osteoporosis after 60. BMJ (1990) 1.18
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View. Clin J Am Soc Nephrol (2015) 1.18
A review of anabolic therapies for osteoporosis. Arthritis Res Ther (2003) 1.14
Fluoride and bone--quantity versus quality. N Engl J Med (1990) 1.08
Genetic background influences fluoride's effects on osteoclastogenesis. Bone (2007) 1.06
Recombinant human parathyroid hormone. BMJ (2002) 1.06
When bone mass fails to predict bone failure. Calcif Tissue Int (1993) 1.05
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol (2009) 1.02
Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ (1992) 1.00
Treatment of postmenopausal osteoporosis. BMJ (2003) 1.00
Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. BMJ (1990) 0.99
HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int (2003) 0.96
Medicine in the elderly. Postgrad Med J (1991) 0.93
Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy. Can Fam Physician (1998) 0.91
Effects of treatment with fluoride on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2007) 0.90
Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study. J Clin Invest (1995) 0.90
Changes in intracortical microporosities induced by pharmaceutical treatment of osteoporosis as detected by high resolution micro-CT. Bone (2011) 0.89
Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm (2008) 0.89
Strontium ranelate for the treatment of osteoporosis. BMJ (2005) 0.88
In vivo response of strontium and zinc-based ionomeric cement implants in bone. J Mater Sci Mater Med (2002) 0.87
Cochlear otosclerosis. Curr Opin Otolaryngol Head Neck Surg (2010) 0.86
Voriconazole-induced periostitis in a patient with overlap syndromes. BMJ Case Rep (2014) 0.85
Fluoride therapy of type I osteoporosis. Clin Rheumatol (1995) 0.85
Water fluoridation: a critical review of the physiological effects of ingested fluoride as a public health intervention. ScientificWorldJournal (2014) 0.85
Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology (Oxford) (2013) 0.84
Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag (2006) 0.83
Encapsulation of apatite particles for improvement in bone regeneration. J Mater Sci Mater Med (2003) 0.82
Glucocorticoid-induced osteoporosis: treatment update and review. Ther Adv Musculoskelet Dis (2009) 0.82
Hip fracture incidence before and after the fluoridation of the public water supply, Rochester, Minnesota. Am J Public Health (1993) 0.82
Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis (1997) 0.81
Influence of fracture criteria on the outcome of a randomized trial of therapy. Osteoporos Int (1998) 0.81
Lifelong calcium intake and prevention of bone fragility in the aged. Calcif Tissue Int (1991) 0.81
Strontium ranelate: a novel mode of action leading to renewed bone quality. Osteoporos Int (2005) 0.81
Peak bone mass and osteoporosis prevention. Osteoporos Int (1993) 0.81
Osteoporosis: the increasing role of the orthopaedist. Iowa Orthop J (1999) 0.80
The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus. Rev Diabet Stud (2008) 0.80
Medical treatment of vertebral osteoporosis. Eur Spine J (2003) 0.80
The three-dimensional microstructure of trabecular bone: Analysis of site-specific variation in the human jaw bone. Imaging Sci Dent (2013) 0.80
Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int (2003) 0.80
Is the metatarsal fracture in postmenopausal women an osteoporotic fracture? A cross-sectional study on 113 cases. Osteoporos Int (1997) 0.79
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int (2003) 0.79
Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int (1997) 0.79
High fluoride and low calcium levels in drinking water is associated with low bone mass, reduced bone quality and fragility fractures in sheep. Osteoporos Int (2014) 0.79
Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporos Int (1997) 0.79
Infrared spectroscopic assessment of the inflammation-mediated osteoporosis (IMO) model applied to rabbit bone. J Biol Phys (2012) 0.79
Acute and Stress-related Injuries of Bone and Cartilage: Pertinent Anatomy, Basic Biomechanics, and Imaging Perspective. Radiology (2016) 0.78
Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action. Calcif Tissue Int (1991) 0.78
Live birth is the correct outcome for clinical trials evaluating therapy for the infertile couple. Fertil Steril (2014) 0.78
Bone density measurements. Calcif Tissue Int (1991) 0.78
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World J Gastroenterol (2011) 0.78
Evaluating the impact of municipal water fluoridation on the aquatic environment. Am J Public Health (1990) 0.78
Advances in Controlled Drug Delivery for Treatment of Osteoporosis. Curr Osteoporos Rep (2016) 0.77
Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporos Int (1997) 0.77
Serum fluoride and serum osteocalcin levels in response to a novel sustained-release monofluorophosphate preparation: comparison with plain monofluorophosphate. Osteoporos Int (1997) 0.77
Fluoride salts for vertebral osteoporosis: the benefit-to-risk ratio depends on the cumulative dose reaching bone. Osteoporos Int (1993) 0.77
Effect of fluoride in postmenopausal osteoporosis. N Engl J Med (1990) 0.76
Understanding osteoporosis. West J Med (1991) 0.76
Role and evolution of therapeutic options. Osteoporos Int (1996) 0.76
Management of established osteoporosis. Br J Clin Pharmacol (1998) 0.76
Does the French general practitioner correctly investigate and treat osteoporosis? Groupe Rhumatologique d'Etudes Cliniques de Midi-Pyrénées. Clin Rheumatol (1998) 0.75
How precise is dental volumetric tomography in the prediction of bone density? Int J Dent (2012) 0.75
Long-term treatment with odanacatib maintains normal trabecular biomechanical properties in ovariectomized adult monkeys as demonstrated by micro-CT-based finite element analysis. Bone Rep (2017) 0.75
Treatment of osteoporosis: current and future. Ann Rheum Dis (1991) 0.75
Osteoprotective Effect of Echinocystic Acid, a Triterpone Component from Eclipta prostrata, in Ovariectomy-Induced Osteoporotic Rats. PLoS One (2015) 0.75
Fluoride treatment in osteoporosis. Postgrad Med J (1991) 0.75
[Osteoporosis in 1993. An information update]. Can Fam Physician (1994) 0.75
Osteoporosis: whose problem is it? Ann Rheum Dis (1992) 0.75
Water fluoridation. Meta-analysis of fluoridation and fractures has been done. BMJ (2001) 0.75
Intermittent Nitrate Use and Risk of Hip Fracture. Am J Med (2016) 0.75
Osteoporosis--an opportunity to prevent being missed. Postgrad Med J (1991) 0.75
Preventive effect of crocin on osteoporosis in an ovariectomized rat model. Evid Based Complement Alternat Med (2014) 0.75
Osteoporosis at the end of the century. West J Med (1991) 0.75
Fluoride treatment of osteoporosis: cyclical non-blinded or continuous blinded studies? Osteoporos Int (1993) 0.75
Prevention of corticosteroid bone loss. Osteoporos Int (1993) 0.75
Is fluoride treatment justified today? Calcif Tissue Int (1991) 0.75
Rethinking the Appraisal and Approval of Drugs for Fracture Prevention. Front Pharmacol (2017) 0.75
Patient Centered Outcomes in Periodontal Treatment-An Evidenced Based Approach. J Clin Diagn Res (2017) 0.75
Voriconazole-induced periostitis: beyond post-transplant patients. Skeletal Radiol (2016) 0.75
Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy. Osteoporos Int (1997) 0.75
Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet (2003) 11.91
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Risk of connective-tissue diseases and other disorders after breast implantation. N Engl J Med (1994) 9.25
Hip fractures in the elderly: a world-wide projection. Osteoporos Int (1992) 9.08
Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51
Involutional osteoporosis. N Engl J Med (1986) 8.20
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Psychotropic drug use and the risk of hip fracture. N Engl J Med (1987) 7.53
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone (1995) 5.76
Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res (1997) 5.69
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) (1982) 5.29
A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am Rev Respir Dis (1992) 5.22
Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA (1996) 5.17
Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med (1980) 4.96
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology (1992) 4.84
Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res (1992) 4.75
Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res (1997) 4.74
Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71
Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology (2007) 4.28
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab (1998) 4.28
A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res (1998) 4.24
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med (1992) 4.19
The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology (1993) 4.18
Surgical management of Meckel's diverticulum. An epidemiologic, population-based study. Ann Surg (1994) 4.16
Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke (1996) 4.13
Potential effect of authorization bias on medical record research. Mayo Clin Proc (1999) 4.01
Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology (1991) 3.90
The prevention and treatment of osteoporosis. N Engl J Med (1992) 3.90
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med (1982) 3.77
Lymphoid neogenesis in rheumatoid synovitis. J Immunol (2001) 3.63
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol (2000) 3.62
Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest (1981) 3.60
Carpal tunnel syndrome in Rochester, Minnesota, 1961 to 1980. Neurology (1988) 3.40
Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res (2000) 3.36
Thoracic aortic aneurysms: a population-based study. Surgery (1982) 3.36
Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc (1990) 3.34
Epidemiology of vertebral fractures in women. Am J Epidemiol (1989) 3.27
Perturbation of the T-cell repertoire in patients with unstable angina. Circulation (1999) 3.20
The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol (1980) 3.19
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Epidemiology of cervical radiculopathy. A population-based study from Rochester, Minnesota, 1976 through 1990. Brain (1994) 3.07
Incidence of spontaneous pneumothorax in Olmsted County, Minnesota: 1950 to 1974. Am Rev Respir Dis (1979) 3.06
T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 3.06
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum (1999) 2.98
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med (1999) 2.98
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation (1989) 2.94
Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop Relat Res (1981) 2.93
Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest (1982) 2.92
Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol (2000) 2.89
Normal axial alignment of the lower extremity and load-bearing distribution at the knee. Clin Orthop Relat Res (1990) 2.86
Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum (1984) 2.85
Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int (1999) 2.83
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood (1992) 2.81
Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc (1999) 2.80
Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med (1986) 2.80
Epidemiologic features of humeral fractures. Clin Orthop Relat Res (1982) 2.79
Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int (1979) 2.79
Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke (2000) 2.78
Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol (2001) 2.78
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Risk factors associated with symptoms of gastroesophageal reflux. Am J Med (1999) 2.75
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74
Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int (2008) 2.72
A biomechanical study of normal functional elbow motion. J Bone Joint Surg Am (1981) 2.71
Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation (1999) 2.71
Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol (2000) 2.68
Intercessory prayer and cardiovascular disease progression in a coronary care unit population: a randomized controlled trial. Mayo Clin Proc (2001) 2.61
Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res (1993) 2.59
Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke (1999) 2.56
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol (1992) 2.54
The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum (1999) 2.50
Long-term survival of a cohort of community residents with asthma. N Engl J Med (1994) 2.47